Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vocuff-AM is a combination cough syrup marketed by Skyways Healthcare, primarily used for the relief of productive cough associated with bronchospasm in conditions such as bronchitis and bronchial asthma. It contains four active ingredients: ambroxol, a mucolytic agent that thins and loosens mucus; terbutaline, a beta-2 adrenergic agonist that acts as a bronchodilator to relax airway muscles; guaifenesin, an expectorant that increases the volume and reduces the viscosity of secretions in the trachea and bronchi; and menthol, which provides a cooling sensation and mild local anesthetic effect to soothe throat irritation. As a branded generic product sold through the PCD (Propaganda Cum Distribution) franchise model in India, it is an established formulation rather than a novel clinical candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol + terbutaline + guaifenesin + menthol.